Diagnostic value of 123I-IMT SPECT in the follow-up of head and neck cancer

Onkologie

Volumn 29, Issue 4, 2006, Pages 147-152

  Plotkin, Michail ^a   Wurm, Reinhard ^a   Kuczer, David ^a   Wust, Peter ^a   Michel, Roger ^a   Denecke, Timm ^a   Ruf, Juri ^a   Schlenger, Lorenz ^a   Bischoff, Annet ^a   Felix, Roland ^a   Amthauer, Holger ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Head and neck cancer; L 3 123I iodine alpha methyl tyrosine; SPECT

Indexed keywords

ALPHA METHYLTYROSINE I 123; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG; 3 IODO ALPHA METHYLTYROSINE; 3-IODO-ALPHA-METHYLTYROSINE; DIAGNOSTIC AGENT; METIROSINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RELAPSE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG DISTRIBUTION; DRUG UPTAKE; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HISTOLOGY; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; RECURRENT CANCER; SCINTILLATION CAMERA; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE DISTRIBUTION; CLINICAL TRIAL; HEAD AND NECK TUMOR; METHODOLOGY; PROGNOSIS; REPRODUCIBILITY; SCINTISCANNING; TREATMENT OUTCOME; TUMOR RECURRENCE;

FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; METHYLTYROSINES; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 33645655064     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092025     Document Type: Article

References (50)

1. Boring CC, Squires TS, Tong TS: Cancer statistics,1992. CA Cancer J Clin 1992;42:19-38.
2. Khuri FR, Shin DM, Glisson BS, Lippmann SM, Hong WK: Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future developments. Semin Oncol 2000;27:25-33.
3. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK: Head and neck cancer. N Engl J Med 1993;328:184-94.
4. Gath HJ, Brakenoff RH: Minimal residual disease in head and neck cancer. Cancer Metastasis Rev 1999;18:109-126.
5. Myers E, Leffall L: Head and Neck Oncology: Diagnosis, Treatment and Rehabilitation. Boston, Little Brown, 1991.
6. Dunne AA, Budach VG, Wagner W, Werner JA: Management of No neck in head and neck cancer: current controversies. Onkologie 2004;27:363-367.
7. Leibel SA, Scott CB, Mohiuddin M, Marcial VA, Coia LR, Davis LW, Fuks Z: The effect of local-regional control on distant metastatic dissemination in carcinoma of the head and neck: results of an analysis from the RTOG head and neck database. Int J Radiat Oncol Biol Phys1991;21:549-556.
8. Pigott K, Dische S, Saunders MI: Where exactly does failure occur after radiation in head and neck cancer? Radiother Oncol 1995;37:17-19.
9. Bronstein AD, Nyberg DA, Schrarzt AN, Shuman WP, Griffin BR: Soft-tissue changes after head and neck radiation: CT findings. Am J Neuroradiol 1989;10:171-175.
10. Som PM: Detection of metastasis in cervical lymph nodes: CT and MR criteria and differential diagnosis. Am J Roentgenol 1992;158:961-969.
11. Chisin R: Nuclear medicine in head and neck oncology: reality and perspectives. J Nucl Med 1999;40:91-95.
12. Davis JP, Maisey NM, Chevreton EB: Positron emission tomography: a useful imaging technique for otolaryngology, head and neck surgery? J Laryngol Otol 1998;112:125-127.
13. Baum U, Anders K, Steinbichler G, Lell M, Greess H, Riedel T, Kachelriess M, Kalender WA, Bautz WA: Improvement of image quality of multislice spiral CT scans of the head and neck region using a raw data-based multidimensional adaptive filtering (MAF) technique. Eur Radiol 2004;14:1873-1881.
14. Henze M, Mohammed A, Mier W, Rudat V, Dietz A, Nollert J, Eisenhut M, Haberkorn U: Pretreatment evaluation of carcinomas of the hypopharynx and larynx with 18F-fluorodeoxyglucose, 123I-alpha-methyl-L-tyrosine and 99mTc-hexakis-2-methoxyisobutylisonitrile. Eur J Nucl Med Mol Imaging 2002;29:324-330.
15. Dierickx LO, Everaert H, Deron P, Voordeckers M, Lahoutte T, Bossuyt A: Evaluation of the response to therapy of head and neck squamous cell carcinoma by using 3-[123I]iodo-L-alpha-methyl tyrosine and single photon emission tomography. Nucl Med Commun 2003;24:633-641.
16. Flamen P, Bernheim N, Deron P, Cavehers V, Chavatte K, Franken PR, Bossuyt A: Iodine-123 alpha-methyl-1-tyrosine single-photon emission tomography for the visualization of head and neck squamous cell carcinomas. Eur J Nucl Med 1998;25:177-181.
17. Dierickx LO, Lahoutte T, Deron P, Caveliers V, Vanhove C, Everaert H, Bossuyt A: Diagnosis of recurrent head and neck squamous cell carcinoma with 3-[123I]iodo-L-alpha-methyltyrosine SPET. Eur J Nucl Med 2001;28:282-287.
18. Krummreich C, Holsbach M, Stöcklin G: Direct electrophilic radioiodination of tyrosine analogues: their in-vivo stability and brain uptake in mice. Appl Radiat Isot 1994 ;45:929-935.
19. Plotkin M, Wurm R, Eisenacher J, Szerewicz K, Michel R, Schlenger L, Pech M, Denecke T, Kuczer D, Bischoff A, Felix R, Amthauer H: Combined SPECT/CT imaging using 123I-IMT in the detection of recurrent or persistent head and neck cancer. Eur Radiol 2006;16:503-11.
20. Lapela M, Grenman R, Kurki T, Joensuu H, Leskinen S, Lindholm P, Haaparanta M, Ruotsalainen U, Minn H: Head and neck cancer: detection of recurrence with PET and 2-[F-18]fluoro-2-deoxy-D-glucose. Radiology 1995;197:205-211.
21. Farber LA, Benard F, Machtay M, Smith RJ, Weber RS, Weinstein GS, Chalian AA, Alavi A, Rosenthal DI: Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography. Laryngoscope 1999;109:970-975.
22. Fischbein NJ, AAssar OS, Caputo GR, Kaplan MJ, Singer MI, Price DC, Dillon WP, Hawkins RA: Clinical utility of positron emission tomography with 18F-fluorodeoxyglucose in detecting residual/recurrent squamous cell carcinoma of the head and neck. Am J Neuroradiol 1998;19:1189-1196.
23. Kao CH, ChangLai SP, Chieng PU, Yen RF, Yen TC: Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with 18-fluoro-2-deoxyglucose positron emission tomography and comparison with computed tomography. J Clin Oncol 1998;16:3550-3555.
24. Wong RJ, Lin DT, Schoder H, Patel SG, Gonen M, Wolden S, Pfister DG, Shah JP, Larson SM, Kraus DH: Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 2002;20:4199-4208.
25. Schmidt M, Schmalenbach M, Jungehülsing M, Thiessen P, Dietlein M, Schröder U, Eschner W, Stennert E, Schicha H: 18F-FDG PET for detecting recurrent head and neck cancer, local lymph node involvement and distant metastases. Comparison of qualitative visual and semiquantitative analysis. Nuklearmedizin 2004;43:91-101.
26. Li P, Zhuang H, Mozley D, Dennitis A, Yen D, Machtay M, Smith R, Alavi A: Evaluation of recurrent squamous cell carcinoma of the head and neck with EDG positron emission tomography. Clin Nucl Med 2001;26:131-135.
27. Tomura N, Watanabe O, Omachi K, Sakuma I, Takahashi S, Otani T, Kidani H, Watarai J: Image fusion of thallium-201 SPECT and MR imaging for the assessment of recurrent head and neck tumors following flap reconstructive surgery. Eur Radiol 2004;14:1249-1254.
28. Leskinen-Kallio S, Nagren K, Lehikoinen P, Ruotsalainen U, Teras M, Joensuu H: Carbon-11-methionine and PET is an effective method to image head and neck cancer. J Nucl Med 1992;33:691-695.
29. Lindholm P, Leskinen-Kallio S, Grenman R, Lehikoinen P, Nagren K, Teras M, Ruotsalainen U, Joensuu H: Evaluation of response to therapy in head and neck cancer by positron emission tomography and 11C-methionine. Int J Rad Oncol Biol Phys 1995;32:787-794.
30. Nuutinen J, Jyrkkio S, Lehikoinen P, Lindholm P, Minn H: Evaluation of early response to radiotherapy in head and neck cancer measured with [11C]methionine-positron emission tomography. Radiother Oncol 1999;52:225-232.
31. Chesnay E, Babin E, Constans JM, Agostini D, Bequignon A, Regeasse A, Sobrio F, Moreau S: Early response to chemotherapy in hypophyryngeal cancer: assessment with 11C-methionine PET. Correlation with morphologic response, and clinical outcome. J Nucl Med 2003;44:526-532.
32. Lowe V, Stack B. PET imaging in head and neck cancer; in Valk P et al. (eds.): Positron Emission Tomography - Basic Science and Clinical Practice. London, Springer, 2003, pp 535-546.
33. Liu SH, Chang JT, Ng SH, Chan SC, Yen TC: False positive fluorine-18 fluorodeoxy-D-glucose positron emission tomography finding caused by osteoradionecrosis in a nasopharyngeal carcinoma patient. Br J Radiol 2004;77:257-260.
34. Eichhorn T, Schroeder HG, Glanz H, Schwerk WB: Histologically controlled comparison of palpation and sonography in the diagnosis of cervical lymph node metastases. Laryngol Rhinol Otol 1987;66:266-274.
35. Golder WA: Lymph node diagnosis in oncologic imaging: a dilemma still waiting to be solved. Onkologie 2004;27:194-199.
36. Yamada S, Kubota K, Kubota R, Ido T, Tamashashi N: High accumulation of fluorine-fluorodeoxyglucose in terpentine-induced inflammatory tissue. J Nucl Med 1995;36:1301-1306.
37. Plotkin M, Hautzel H, Krause BJ, Mohr S, Langen KJ, Müller HW: Fluorine-18-labeled fluorodeoxyglucose-positron emission tomography studies of acute brainstem Lyme neuroborreliosis. Case report. J Neurosurg 2005;102:927-929.
38. Reinhardt MJ, Kubota K, Yamada S, Iwata R, Yaegashi H: Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of flouorodeoxyglucose, L-methionine and thymidine. J Nucl Med 1997;38:280-287.
39. Hautzel H, Müller-Gärtner HW: Early changes in fluorine-18-FDG uptake during radiotherapy. J Nucl Med 1997;38:1384-1386.
40. Shreve PD, Anzai Y, Wahl RL: Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographies 1999;19:61-77.
41. Langen KJ, Coenen HH, Roosen N, Kling P, Muzik O, Herzog H, Kuwert T, Stöcklin G, Feinendegen LE: SPECT studies of brain tumors with L-3-[123]iodo-α-methyl tyrosine: comparison with PET, 124IMT and first clinical results. J Nucl Med 1990;31:281-286.
42. Langen KJ, Ziemons K, Kiwit JCW, Herzog H, Kuwert T, Bock WJ, Stöcklin G, Feinendegen LE, Müller-Gärtner HW: 3-[123I]iodo-alpha-methyl tyrosine and [methyl-11C]-L-methionine uptake in cerebral gliomas: a comparative study using SPECT and PET. J Nucl Med 1997;38:517-522.
43. Langen KJ, Pauleit D, Coenen HH: 3-(123I)-iodo-a-methyl-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 2002;29:625-631.
44. Ruf J, Amthauer H, Oettle H, Steinmuller T, Plotkin M, Pelzer U, Scholman HJ, Felix R, Wust P: Role of F18-FDG PET for monitoring of radiochemotherapy - estimation of detectable number of tumour cells. Onkologie 2004;27:287-290.
45. Greven KM, Williams DW 3rd, Keyes JW Jr, McGuirt WF, Watson NE Jr, Randall ME, Raben M, Geisinger KR, Cappellari JO: Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer 1994;74:1355-1359.
46. Plotkin M, Amthauer H, Eisenacher J, Wurm R, Michel R, Wust R, Stockhammer F, Gutberlet M, Röttgen R, Ruf J, Felix R: Value of 123I-IMT SPECT for diagnosis of recurrent non-astrocytic intracranial tumours. Neuroradiology 2005;47:18-26.
47. Pauleit D, Stoffels G, Schaden W, Schaden W, Hamacher K, Bauer D, Tellmann L, Herzog H, Broer S, Coenen HH, Langen KJ: PET with O-(2-[18F]fluoroethyl)-L-tyrosine (FET) in peripheral tumors: first clinical results. J Nucl Med 2005;64:411-416.
48. Schwartz LH, Ozsahin M, Zhang GN, Touboul E, de Vataire F, Andolenko P, Lacau-Saint-Guily J, Laugier A, Schlienger M: Synchronous and metachronous head and neck carcinomas. Cancer 1994;74:1933-1938.
49. Reske SN, Dankerl A, Glatting G, Mottaghy FM, Blumstein NM: Stellenwert der PET bei Kopf-Hals-Tumoren. Laryngo-Rhino-Othol 2004;83:391-406.
50. Marcy PY, Magne N, Bailet C, Pivot X, Dassonville O, Poissonnet G, Demard F. Liver metastases from head and neck squamous cell carcinomas: radiological and biological features. Onkologie 2004;27:157-160.